E
Eunice L. Kwak
Researcher at Harvard University
Publications - 148
Citations - 24080
Eunice L. Kwak is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & FOLFIRINOX. The author has an hindex of 49, co-authored 146 publications receiving 21705 citations.
Papers
More filters
Journal ArticleDOI
A matter of timing: is there a role for radiation in locally advanced pancreatic cancer, and if so, when?
TL;DR: The role of radiation therapy in the management of locally advanced pancreatic cancer is controversial and the need for further research into this area is unclear.
Journal ArticleDOI
A phase II study of gemcitabine (G), bevacizumab (B), and erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas
Lawrence S. Blaszkowsky,Andrew X. Zhu,Thomas A. Abrams,Craig C. Earle,Eunice L. Kwak,Aram F. Hezel,Jeffrey A. Meyerhardt,Kerry Horgan,Hui Zheng,David P. Ryan +9 more
TL;DR: This data indicates that the addition of E to G has resulted in a modest, yet statistically significant improvment in clinical trials evaluating combination therapy for pancreatic cancer.
Journal ArticleDOI
FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.
Janet E. Murphy,Jennifer Y. Wo,David P. Ryan,Wenqing Jiang,Beow Y. Yeap,Lawrence S. Blaszkowsky,Eunice L. Kwak,Jill N. Allen,Jeffrey W. Clark,Jason E. Faris,Andrew X. Zhu,Lipika Goyal,Harvey J. Mamon,Keith D. Lillemoe,Thomas F. DeLaney,Carlos Fernandez-del Castillo,Cristina R. Ferrone,Theodore S. Hong +17 more
TL;DR: In this paper, the authors evaluated neoadjuvant F-NOX followed by individualized chemoradiation (CRT) for borderline resectable pancreatic cancer (BRPC) due to the improved response rate compared to gemcitabine.
Journal ArticleDOI
Phase 1 study of E7046, an inhibitor of the PGE2 receptor EP-4, that targets immunosuppressive myeloid cells in the tumor microenvironment (NCT02540291).
TL;DR: This is a first-in-human study of E7046 to determine safety/tolerability, maximum tolerated dose (MTD), and/or recommended phase 2 dose (RP2D) of this selective prostaglandin E2 receptor-type-4 small-molecule inhibitor.
Journal ArticleDOI
Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.
Theodore S. Hong,David P. Ryan,Darrell R. Borger,Lawrence S. Blaszkowsky,Beow Y. Yeap,Vikram Deshpande,Jennifer Y. Wo,Raymond C. Wadlow,Eunice L. Kwak,Jill N. Allen,Jeffrey W. Clark,Andrew X. Zhu,Cristina R. Ferrone,Harvey J. Mamon,Judith Adams,Barbara Winrich,Tarin Grillo,Thomas F. DeLaney,Carlos Fernandez-del Castillo +18 more
TL;DR: The safety and efficacy of a one-week course of pre-op CRT with PBT and cape followed by early pancreaticoduodenectomy (PD) followed by surgery with 6 mo of gemcitabine is explored.